This combination form is indicated for the reduction of thrombotic events as follows: For patients with a history of recent myocardial infarction (MI), recent stroke or established peripheral arterial disease, This combination form has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not) and other vascular death. For patients with acute coronary syndrome (unstable angina/non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG. This combination form has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia

Recent MI, Recent Stroke, or Established Peripheral Arterial Disease The recommended daily dose is one tablet daily. For patients with acute coronary syndrome (unstable angina/non-Q-wave MI), should be initiated with a 4 tablet stat loading dose and then continued at one tablet daily.